<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95762">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01899456</url>
  </required_header>
  <id_info>
    <org_study_id>5548/12</org_study_id>
    <nct_id>NCT01899456</nct_id>
  </id_info>
  <brief_title>Impact of Sympathetic Renal Denervation- a Study in Patients After Renal Transplantation</brief_title>
  <acronym>ISAR-denerve</acronym>
  <official_title>A Randomized Safety and Efficacy Study Investigating the Effects of Catheter-based Renal Denervation in Patients After Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Nephrology, Klinikum rechts der Isar, Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <authority>Germany: Federal Office for Radiation Protection</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aiming to document the safety and effectiveness of renal denervation in
      patients after renal transplantation with hypertension. Catheter-based renal denervation
      will be performed using CE marked, percutaneous Symplicity catheter.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and efficacy of renal denervation in patients after renal transplantation</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Effect on blood pressure including office, ABPM, and home-based measurements. Number of adverse events. Changes of antihypertensive medications. Effects on renal function assessed with glomerular filtration rate. Renovascular safety (renal artery stenosis) assessed by duplex ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of renal denervation in patients after renal transplantation on different organ systems.</measure>
    <time_frame>Baseline to 6 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Effects on sympathetic activity assessed by heart rate variability and post extrasystolic potentiation. Glucose metabolism and insulin resistance (fasting and during oGTT). Hospitalization rates (eg. hypertensive emergencies, heart failure, etc).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypertension</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Renal Transplantation</condition>
  <condition>Sympathetic Activity</condition>
  <arm_group>
    <arm_group_label>Medical therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best medical therapy using guideline recommended drugs in each disease state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter-based renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation will be performed in the native renal arteries of patients after renal transplantation. Access side is the contralateral femoral artery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter-based renal denervation</intervention_name>
    <arm_group_label>Catheter-based renal denervation</arm_group_label>
    <other_name>Renal denervation with Symplicity Catheter Medtronic/Ardian</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient after renal transplantation (&gt; 6 month) without resection of native kidneys

          -  systolic blood pressure &gt;=150 mmHg

          -  on 3 or more antihypertensive medications

          -  Individual is 18 years of age

          -  Individual agrees to have all procedures performed, and is competent and  willing to
             provide written, informed consent to participate in the registry.

        Exclusion Criteria:

          -  secondary causes and a white coat hypertension

          -  renal artery abnormalities

          -  eGFR &lt; 45mL/min (MDRD)

          -  angina

          -  severe Aortic valve stenosis

          -  Individual is pregnant, nursing or planning to be pregnant

          -  other
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Unversität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>July 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität München</investigator_affiliation>
    <investigator_full_name>Simon Schneider</investigator_full_name>
    <investigator_title>Simon Schneider, MD; 1.Medizinische Klinik und Poliklinik, Klinikum rechts der Isar</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
